



Summary of capital reduction pursuant to Article 32 of the Danish Capital Markets Act

With reference to Novozymes' Company announcement No. 4/2019, a reduction of DKK 12,000,000 in the Company's B common stock via the cancellation of 6,000,000 B shares of the Company's treasury stock was carried out on March 29, 2019, following the adoption of this proposal at the Company's annual shareholders' meeting on February 27, 2019.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act No. 12 of January 8, 2018, the Company announces that its total capital stock as of today consists of nominally DKK 582,000,000, divided into 291,000,000 shares, corresponding to 53,743,600 A shares and 237,256,400 B shares with a nominal value of DKK 2 each and a total of 1,011,984,800 voting rights.

29. marts, 2019

Company announcement No. 5

Contact information

novozymesIR@novozymes.com

Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Carl Ahlgren
+45 3077 2783
cxal@novozymes.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozymes A/S CVR number: 10 00 71 27 LEI: 529900T6WNZXD2R3JW38

Novozymes A/S

Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000

Rethink Tomorrow

novozymes 